Provided by Tiger Fintech (Singapore) Pte. Ltd.

Purple Biotech Ltd.

2.58
-0.1100-4.10%
Post-market: 2.50-0.0748-2.90%16:37 EDT
Volume:12.75K
Turnover:33.22K
Market Cap:6.82M
PE:-0.58
High:2.74
Open:2.74
Low:2.50
Close:2.69
Loading ...

Purple Biotech Q4 EPADS $(0.26)

Benzinga
·
10 Mar

Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Dow Jones
·
10 Mar

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

GlobeNewswire
·
05 Mar

Purple Biotech Ltd expected to post a loss of $1.80 a share - Earnings Preview

Reuters
·
28 Feb

Purple Biotech Moves NT219 Into Phase 2 Trial Aimed at Overcoming Tumor Resistance in Head, Neck Cancer Therapies

MT Newswires Live
·
18 Feb

Purple Biotech advances NT219 into Phase 2 head, neck cancer trial

TIPRANKS
·
18 Feb

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

GlobeNewswire
·
18 Feb

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

GlobeNewswire
·
03 Feb

Purple Biotech Secures $2.8 Million for Oncology Advancements

TIPRANKS
·
05 Dec 2024

ADRs End Lower; Purple Biotech Ltd. Declines 27%

Dow Jones
·
05 Dec 2024

Purple Biotech Signs Securities Purchase Agreement

TIPRANKS
·
05 Dec 2024

Purple Biotech Secures $2.8 Million Through ADS Offering

TIPRANKS
·
04 Dec 2024

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

Zacks
·
04 Dec 2024

ADRs Advance; Purple Biotech Ltd. Climbs 150%

Dow Jones
·
03 Dec 2024

Economic Data in Focus as US Equity Futures Waver Pre-Bell

MT Newswires Live
·
02 Dec 2024

Purple Biotech Shares Jump on Positive Phase 2 Cancer Drug Study Results

Dow Jones
·
02 Dec 2024

Purple Biotech Reports Positive Phase 2 Study Results for CM24 Plus Nivolumab and Chemotherapy in Patients With Pancreatic Cancer

MT Newswires Live
·
02 Dec 2024

Purple Biotech Price Target Maintained With a $33.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Nov 2024

Purple Biotech Ltd expected to post a loss of $3.30 a share - Earnings Preview

Reuters
·
15 Nov 2024

Purple Biotech Unveils Promising Biomarker for Cancer Therapy

TIPRANKS
·
04 Nov 2024